SpringerLink
Log in

Psoriasis in Norway: a prescription-based registry study of psoriasis-associated comorbidities

  • Clinical Report
  • Published:
European Journal of Dermatology

Abstract

Background

Psoriasis is an inflammatory skin disease, frequently associated with comorbidities.

Objectives

To characterize comorbidities associated with skin psoriasis using real-world data.

Materials & Methods

The study was conducted in Norway, taking advantage of the universal healthcare system with equal access to healthcare and a mandatory prescription reporting system that applies to all hospitals and clinics. The study focused on patients registered in the Norwegian Prescription Database (NorPD) who had either a diagnosis code indicating skin psoriasis alone or in combination with diagnosis codes for pre-selected comorbidities.

Results

Between 2004 and 2020, a total of 272,725 patients diagnosed with skin psoriasis were identified in NorPD, and 84,432 patients received their first prescription for skin psoriasis between 2015 and 2020. Among these, patients who received prescriptions for pre-selected comorbidities, either before or after initial prescription for psoriasis treatment, were included in the study. The most common prescriptions for patients with skin psoriasis were for primary prevention of atherosclerotic disease (22.6%), established atherosclerotic disease (19.3%), and depression (18.4%). These were closely followed by prescriptions for other comorbidities such as heart failure (16.1%), type II diabetes mellitus (9.4%), hypertension (9.4%), anxiety (7.8%), psoriatic arthritis (5.5%), acute myocardial infarction (4.2%), hypertensive cardiac disease (3.0%), ulcerative colitis (2.4%), type I diabetes mellitus (2.2%), secondary prophylaxis after myocardial infarction (1.6%), and Crohn’s disease (1.0%).

Conclusion

Patients with skin psoriasis have a high number of prescriptions not only for their psoriasis but also for many other conditions compared to reports in the literature on the general population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Shah K, Mellars L, Changolkar A, Feldman SR. Real-world burden of comorbidities in US patients with psoriasis. J Am Acad Dermatol 2017; 77: 287–92.

    Article  PubMed  Google Scholar 

  2. Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Brit J Dermatol 2020; 182: 840–8.

    Article  CAS  Google Scholar 

  3. Solberg SM. Psoriasis in norway: a prescription-based registry study of incidence and prevalence. Acta Derm Venereol 2023; 103: adv4591.

    Article  PubMed  Google Scholar 

  4. Grozdev I, Korman N, Tsankov N. Psoriasis as a systemic disease. Clin Dermatol 2014; 32: 343–50.

    Article  PubMed  Google Scholar 

  5. Villanova F, Di Meglio P, Nestle FO. Biomarkers in psoriasis and psoriatic arthritis. Ann Rheum Dis 2013; 72: 104–10.

    Article  Google Scholar 

  6. Elmets CA, Leonardi CL, Davis DMR et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 2019; 80: 1073–113.

    Article  PubMed  Google Scholar 

  7. Takeshita J, Grewal S, Langan SM et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol 2017; 76: 377–90.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Griffiths CEM, Barker JNWN. Psoriasis 1 - Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263–71.

    Article  CAS  PubMed  Google Scholar 

  9. Danielsen K. Increased risk of death in patients with psoriasis: disease or lifestyle? Br J Dermatol 2019; 180: 3–4.

    Article  CAS  PubMed  Google Scholar 

  10. Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol 2018; 5: 9.

    Google Scholar 

  11. Sajja AP, Joshi AA, Teague HL, Dey AK, Mehta NN. Potential immunological links between psoriasis and cardiovascular disease. Front Immunol 2018; 1: 9.

    Google Scholar 

  12. Solak Y, Afsar B, Vaziri ND et al. Hypertension as an autoimmune and inflammatory disease. Hypertens Res 2016; 39: 567–73.

    Article  CAS  PubMed  Google Scholar 

  13. Rosset F, Mastorino L, Dapavo P, Quaglino P, Ribero S. Impact of comorbidities in elderly and frail patients and response to biological therapy in psoriasis. Exp Dermatol 2023; 32: 1162–64.

    Article  CAS  PubMed  Google Scholar 

  14. Modalsli EH, Snekvik I, Asvold BO, Romundstad PR, Naldi L, Saunes M. Validity of self-reported psoriasis in a general population: the HUNT study, Norway. J Invest Dermatol 2016; 136: 323–5.

    Article  CAS  PubMed  Google Scholar 

  15. Gelfand JM, Dommasch ED, Shin DB et al. The risk of stroke in patients with psoriasis. J Investig Dermatol 2009; 129: 2411–8.

    Article  CAS  PubMed  Google Scholar 

  16. Boehncke WH, Schon MP. Psoriasis. Lancet 2015; 386: 983–94.

    Article  CAS  PubMed  Google Scholar 

  17. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Brit J Dermatol 2007; 157: 68–73.

    Article  CAS  Google Scholar 

  18. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Archiv Dermatol Res 2006; 298: 321–8.

    Article  Google Scholar 

  19. Lonnberg AS, Skov L. Co-morbidity in psoriasis: mechanisms and implications for treatment. Expert Rev Clin Immunol 2017; 13: 27–34.

    Article  PubMed  Google Scholar 

  20. Danielsen K, Wilsgaard T, Olsen AO, et al. Elevated odds of metabolic syndrome in psoriasis: a population-based study of age and sex differences. Br J Dermatol 2015; 172: 419–27.

    Article  CAS  PubMed  Google Scholar 

  21. Odegaard KM, Hallen J, Lirhus SS, Melberg HO, Halvorsen S. Incidence, prevalence, and mortality of heart failure: a nationwide registry study from 2013 to 2016. ESC Heart Fail 2020; 7: 1917–26.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Lindberg I, Lilja M, Geale K, et al. Incidence of psoriatic arthritis in patients with skin psoriasis and associated risk factors: a retrospective population-based cohort study in Swedish routine clinical care. Acta Derm Venereol 2020; 100: adv00324.

    Article  PubMed  Google Scholar 

  23. Takeshita J, Wang SW, Shin DB, et al. Effect of psoriasis severity on hypertension control a population-based study in the United Kingdom. JAMA Dermatol 2015; 151: 161–9.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Johansen CB, Egeberg A, Jimenez Solem E, Vittrup I, Skov L, Francis Thomsen S. Comorbidities, socioeconomic status, drug use, and health care consumption in Danish women with psoriasis: a nationwide cross-sectional study. Int J Womens Dermatol 2021; 7: 246–58.

    Article  PubMed  Google Scholar 

  25. Dowlati Y, Herrmann N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446–57.

    Article  CAS  PubMed  Google Scholar 

  26. Miller AH, Haroon E, Felger JC. The immunology of behavior-exploring the role of the immune system in brain health and illness. Neuropsychopharmacology 2017; 42: 1–4.

    Article  PubMed  Google Scholar 

  27. Bortolato B, Carvalho AF, Soczynska JK, Perini GI, McIntyre RS. The involvement of TNF-alpha in cognitive dysfunction associated with major depressive disorder: an opportunity for domain specific treatments. Curr Neuropharmacol 2015; 13: 558–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Kringlen E, Torgersen S, Cramer V. A Norwegian psychiatric epidemiological study. Am J Psychiatry 2001; 158: 1091–8.

    Article  CAS  PubMed  Google Scholar 

  29. Modalsli EH, Asvold BO, Snekvik I, Romundstad PR, Naldi L, Saunes M. The association between the clinical diversity of psoriasis and depressive symptoms: the HUNT Study, Norway. J Eur Acad Dermatol Venereol 2017; 31: 2062–8.

    Article  CAS  PubMed  Google Scholar 

  30. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139: 846–50.

    Article  CAS  PubMed  Google Scholar 

  31. Sorensen M, Arneberg F, Line TM, Berg TJ. Cost of diabetes in Norway 2011. Diabetes Res Clin Pract 2016; 122: 124–32.

    Article  CAS  PubMed  Google Scholar 

  32. Snekvik I, Nilsen TIL, Romundstad PR, Saunes M. Psoriasis and cardiovascular disease risk factors: the HUNT Study, Norway. J Eur Acad Dermatol Venereol 2018; 32: 776–82.

    Article  CAS  PubMed  Google Scholar 

  33. Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension a prospective study of US female nurses. Arch Dermatol 2009; 145: 379–82.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Lonnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF. Association of psoriasis with the risk for Type 2 diabetes mellitus and obesity. JAMA Dermatol 2016; 152: 761–7.

    Article  PubMed  Google Scholar 

  35. Khalid U, Hansen PR, Gislason GH, et al. Psoriasis and new-onset diabetes: a Danish nationwide cohort study. Diabetes Care 2013; 36: 2402–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Wolf N, Quaranta M, Prescott NJ et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 2008; 45: 114–6.

    Article  CAS  PubMed  Google Scholar 

  37. Mehta NN, Azfar RS, Shin DB, Neimanns AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010; 31: 1000–6.

    Article  PubMed  Google Scholar 

  38. Gelfand JM, Neimann AL, Shin DB, Wang XM, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. Jama-J Am Med Assoc 2006; 296: 1735–41.

    Article  CAS  Google Scholar 

  39. Mehta NN, Yu YD, Pinnelas R et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011; 124.

  40. Skroza N, Proietti I, Pampena R, et al. Correlations between psoriasis and inflammatory bowel diseases. Biomed Res Int 2013; 2013.

  41. Egeberg A, Mallbris L, Warren RB, et al. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. Brit J Dermatol 2016; 175: 487–92.

    Article  CAS  Google Scholar 

  42. Lirhus SS, Hoivik ML, Moum B, Anisdahl K, Melberg HO. Incidence and prevalence of inflammatory bowel disease in norway and the impact of different case definitions: a nationwide registry study. Clin Epidemiol 2021; 13: 287–94.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Alinaghi F, Calov M, Kristensen LE et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 2019; 80: 251–65 e19.

    Article  PubMed  Google Scholar 

  44. Egeberg A, Skov L, Zachariae C, Gislason GH, Thyssen JP, Mallbris L. Duration of psoriatic skin disease as risk factor for subsequent onset of psoriatic arthritis. Acta Derm Venereol 2018; 98: 546–50.

    Article  PubMed  Google Scholar 

  45. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med 2017; 376: 957–70.

    Article  PubMed  Google Scholar 

  46. Egeberg A, Skov L, Gislason GH, Thyssen JP, Mallbris L. Incidence and prevalence of psoriasis in Denmark. Acta Derm Venereol 2017; 97: 808–12.

    Article  PubMed  Google Scholar 

  47. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011; 20: 303–7.

    Article  PubMed  Google Scholar 

  48. Boehncke WH, Boehncke S. Systemic antipsoriatic therapy may reverse endothelial dysfunction. Br J Dermatol 2011; 164: 1397–8.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Fredrik Arneberg, project lead for Psoriasis in Norway project (PIN). Sandre S. Lirhus, ML Analyse AS for analyses.

Funding

Funding sourcel conflicts of interest: PIN is a public-private collaborative project between the Department of Dermatology, Bergen, Norway with Silje Michelsen Solberg MD, PhD, Psoriasis- and eczema association (PEF), nine pharmaceutical companies (UCB, Novartis, Janssen, Abbvie, Bristol Meyers Squibb, Leo, Lilly, Pfizer, Boehringer Ingelheim) and the Pharmaceutical Industry Association (LMI) in Norway.

Author information

Authors and Affiliations

  1. Department of Dermatology, Haukeland University Hospital, Bergen, Norway

    Silje Michelsen Solberg

  2. Department of Clinical Medicine, University of Bergen, Bergen, Norway

    Silje Michelsen Solberg

Authors
  1. Silje Michelsen Solberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silje Michelsen Solberg.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Solberg, S.M. Psoriasis in Norway: a prescription-based registry study of psoriasis-associated comorbidities. Eur J Dermatol 33, 657–663 (2023). https://doi.org/10.1684/ejd.2023.4585

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2023.4585

Keywords

Search

Navigation